BSE · 530207
Brawn Biotech Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹6 Cr with net profit ₹0 Cr — a 0.53% net margin, versus 2.47% the period before.
Shareholding
As of 2026-09-30
- Promoter52.94%
- Public46.71%
- DII0.35%
3,263 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.5× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Trading · ranked #531 of 693 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,63,802 Cr | 101.43 | 3.71 | 3.66% | 4.59% |
| Avenue Supermarts Limited | ₹2,24,349 Cr | 71.98 | 8.6 | 11.94% | 4.2% |
| Trent Ltd. | ₹1,68,779 Cr | 88.12 | 21.69 | 24.4% | 8.62% |
| FSN E-Commerce Ventures Ltd. | ₹1,04,618 Cr | 314.83 | 63.16 | 19.49% | 2.85% |
| Aditya Infotech Limited | ₹50,886 Cr | 82.37 | 13.87 | 16.16% | 10.38% |
| Vishal Mega Mart Limited | ₹45,148 Cr | 50.19 | 5.7 | 11.37% | 6.45% |
| Aegis Logistics Limited | ₹42,976 Cr | 32.26 | 6.45 | 20.01% | 14.99% |
| Premier Energies Limited | ₹40,670 Cr | 22.98 | 7.88 | 34.23% | 19.11% |
| Redington Limited | ₹27,339 Cr | 13.62 | 2.54 | 18.62% | 1.31% |
| Honasa Consumer Limited | ₹16,378 Cr | 57.17 | 11.02 | 19.03% | 10.3% |
| Brawn Biotech Ltd.(this company) | ₹7 Cr | 8.06 | 1.46 | 18.05% | 4.5% |
AI analysis
AI-generated · google/gemini-2.5-flashBrawn Biotech Ltd. is listed with a market capitalization of Rs 7 Cr. The company reported annual revenue of Rs 1.98 Cr in March 2026, with a negative profit margin of 0%. Its EPS is Rs 0.62 and the book value is Rs 10. For the quarter ending June 2023, revenue was Rs 0.12 Cr.
Positives
- +The company has a low debt-to-equity ratio of 0.
- +Promoter shareholding is above 50% at 52.9412% as of June 2026.
- +There are no shares pledged by the promoters (0%).
Negatives
- −The company reported a negative profit margin of 0%.
- −Return on equity (ROE) and Return on capital employed (ROCE) figures are not available, making it difficult to assess efficiency.
- −The annual revenue has shown fluctuation, decreasing from Rs 4.31 Cr in December 2025 to Rs 1.98 Cr in March 2026.
- −Quarterly net profit was negative at -Rs 0.04 Cr in June 2023.
Financial Performance
Brawn Biotech Ltd. reported annual revenue of Rs 1.98 Cr in March 2026. Prior to this, revenue was Rs 4.31 Cr in December 2025 and Rs 4.89 Cr in September 2025. Quarterly revenue in June 2023 was Rs 0.12 Cr, compared to Rs 0.12 Cr in March 2023.
Profitability & Returns
The company's profit margin stands at 0%. Net profit in March 2026 was Rs 0.58 Cr, a significant increase from Rs 0.05 Cr in December 2025. Quarterly net profit was -Rs 0.04 Cr in June 2023, following a net profit of Rs 0.23 Cr in March 2023.
Balance Sheet
Brawn Biotech Ltd. has a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 10. The company has a PE ratio of 38.69.
Ownership & Pledges
There are no promoter pledges.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.